Moxifloxacin Accord Healthcare (Moxifloxacin Hydrochloride)

Moxifloxacin, the active ingredient in Moxifloxacin Accord Healthcare, is a fluoroquinolone antibiotic presented as an oral tablet for systemic use. It treats bacterial infections such as community‑acquired pneumonia, acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, and skin and skin‑structure infections in adults.

GNH USA supplies Moxifloxacin Accord Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Moxifloxacin is a broad‑spectrum antibacterial that targets common respiratory and skin infections.

Community‑acquired pneumonia: eradicates the causative bacteria to improve lung function and reduce fever. Acute bacterial sinusitis: clears sinus infection, relieving congestion and facial pain. Acute bacterial exacerbation of chronic bronchitis: reduces bacterial load, helping restore normal breathing. Skin and skin‑structure infections: eliminates pathogenic bacteria, promoting wound healing and preventing spread.

Moxifloxacin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or vomiting - Diarrhea or abdominal discomfort - Headache or dizziness - Rash or mild skin itching - Photosensitivity reactions - Transient elevation of liver enzymes

Serious or Rare Side Effects: - Tendon rupture or tendinitis, especially in the Achilles tendon - QT interval prolongation leading to cardiac arrhythmias - Severe allergic reactions such as Stevens‑Johnson syndrome - Clostridioides difficile‑associated colitis - Hepatic failure or significant liver injury - Peripheral neuropathy or central nervous system effects

Before prescribing Moxifloxacin, clinicians should evaluate patient‑specific risk factors and monitor for potential complications.

Assess renal and hepatic function: adjust therapy if impairment is present. Avoid use in patients with known hypersensitivity to fluoroquinolones. Monitor QT interval: caution in patients with cardiac conduction disorders. Use with caution in the elderly: higher risk of tendon injury. Avoid concomitant use with other fluoroquinolones or agents that prolong QT. Store at ambient temperature: keep in the original container, protect from moisture.

Moxifloxacin can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Antacids or supplements containing magnesium or aluminum: reduce absorption. - Warfarin: may increase anticoagulant effect and bleeding risk. - Other QT‑prolonging drugs (e.g., macrolides, antiarrhythmics): heighten arrhythmia risk.

Moderate Interactions (Monitor Closely): - CYP1A2 inhibitors such as fluvoxamine: increase plasma levels. - CYP3A4 inducers like rifampicin: decrease effectiveness. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may raise risk of central nervous system side effects.